Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease

Neurology

Volumn 82, Issue 18, 2014, Pages 1597-1604

  Hong, Jin Yong ^a,c   Oh, Jungsu S ^b   Lee, Injoo ^b   Sunwoo, Mun Kyung ^c   Ham, Jee Hyun ^c   Lee, Ji E ^c   Sohn, Young H ^c   Kim, Jae Seung ^b   Lee, Phil Hyu ^c,d  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Brain Research Institute   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; ENTACAPONE; FLUOROPROPYLCARBOMETHOXYIODOPHENYLNORTROPANE; LEVODOPA; RADIOPHARMACEUTICAL AGENT; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CORPUS STRIATUM; DEPLETION; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; OUTPATIENT DEPARTMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; ANTIPARKINSON AGENTS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TROPANES;

EID: 84902149096     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000385     Document Type: Article

References (38)

1. Blanchet PJ, Allard P, Gregoire L., Tardif F, Bedard PJ Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996; 23: 189-193. (Pubitemid 26302745)
2. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999; 246:1127-1133. (Pubitemid 30021235)
3. Rascol O, Brooks DJ, Korczyn A.D., De Deyn PP, Clarke CE, Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000; 342:1484-1491. (Pubitemid 30318272)
4. Stocchi F, Rascol O, Kieburtz K., et al. Initiating levodopa/ carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68:18-27.
5. Holloway RG, Shoulson I, Fahn S., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-1053. (Pubitemid 38915945)
6. Fahn S, Oakes D, Shoulson I., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
7. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 2000; 123:2297-2305.
8. Kostic V, Przedborski S, Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41:202-205.
9. Arabia G, Zappia M, Bosco D., et al. Body weight, levo-dopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci 2002; 23(SUPPL. 2):S53-S54. (Pubitemid 35355773)
10. Zappia M, Annesi G, Nicoletti G., et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005; 62:601-605. (Pubitemid 40489893)
11. Oliveri RL, Annesi G, Zappia M., et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999; 53:1425-1430. (Pubitemid 29491932)
12. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9:1106-1117.
13. Boyce S, Rupniak NM, Steventon M.J., Iversen SD Nigro-striatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990; 13:448-458. (Pubitemid 20285578)
14. Putterman DB, Munhall AC, Kozell L.B., Belknap JK, Johnson SW Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2007; 323:277-284. (Pubitemid 47443278)
15. Schneider JS. Levodopa-induced dyskinesias in parkinso-nian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989; 34:193-196. (Pubitemid 20008903)
16. Olanow WC, Kieburtz K, Rascol O., et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013; 28:1064-1071.
17. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al.. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49: 298-303. (Pubitemid 32202782)
18. de la Fuente-Fernandez R, Pal PK, Vingerhoets FJ, et al.. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 2000; 107:49-57. (Pubitemid 30077042)
19. Linazasoro G, Antonini A, Maguire R.P., Leenders KL Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. J Neural Transm 2004; 111:497-509. (Pubitemid 38478917)
20. Linazasoro G, Van Blercom N, Bergaretxe A, Inaki F.M., Laborda E., Ruiz Ortega JA. Levodopa-induced dyskine-sias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study. Clin Neuropharmacol 2009; 32: 326-329.
21. Gibb WR, Lees AJ The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51:745-752.
22. Oh M, Kim JS, Kim J.Y., et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med 2012; 53:399-406.
23. Mawlawi O, Martinez D, Slifstein M., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I: accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21:1034-1057. (Pubitemid 32823740)
24. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27:1533-1539. (Pubitemid 47301451)
25. Benamer HT, Patterson J, Wyper D.J., Hadley DM, Macphee GJ, Grosset DG Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000; 15:692-698. (Pubitemid 30479622)
26. Rinne JO, Ruottinen H, Bergman J., Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67:737-741.
27. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 2007; 254:185-190. (Pubitemid 46356050)
28. Bohnen NI, Muller ML, Koeppe R.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009; 73:1670-1676.
29. Parent A, Hazrati LN Functional anatomy of the basal ganglia: I: the cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995; 20:91-127.
30. Morissette M, Samadi P, Hadj Tahar A, Belanger N, Di Paolo T. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:446-454.
31. Carlsson T, Carta M, Munoz A., et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009; 132:319-335.
32. Morrish PK, Sawle GV, Brooks DJ Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996; 119:2097-2103.
33. Nandhagopal R, Kuramoto L, Schulzer M., et al. Longitudinal progression of sporadic Parkinson's disease: a multitracer positron emission tomography study. Brain 2009; 132:2970-2979.
34. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dys-kinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10:2694-2706. (Pubitemid 28362576)
35. Pons R, Syrengelas D, Youroukos S., et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 2013; 28:1058-1063.
36. Hilker R, Schweitzer K, Coburger S., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluoro-dopa F 18 activity. Arch Neurol 2005; 62:378-382. 37. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661.
37. Whone AL, Watts RL, Stoessl A.J., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54:93-101. (Pubitemid 36764985)
38. Parkinson Study Group. Effects of tocopherol and depre-nyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328:176-183.